These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
94 related articles for article (PubMed ID: 22595693)
1. HIV vaccine design: the neutralizing antibody conundrum. Stamatatos L Curr Opin Immunol; 2012 Jun; 24(3):316-23. PubMed ID: 22595693 [No Abstract] [Full Text] [Related]
2. Broadly Neutralizing Antibodies and the Development of Vaccines. Haynes BF; Bradley T JAMA; 2015 Jun 23-30; 313(24):2419-20. PubMed ID: 26103022 [No Abstract] [Full Text] [Related]
3. AIDS/HIV. A boost for HIV vaccine design. Burton DR; Weiss RA Science; 2010 Aug; 329(5993):770-3. PubMed ID: 20705840 [No Abstract] [Full Text] [Related]
4. HIV neutralizing antibodies reignite interest in vaccine. Waltz E Nat Biotechnol; 2012 Mar; 30(3):204-5. PubMed ID: 22398603 [No Abstract] [Full Text] [Related]
5. HIV vaccine development--improving on natural immunity. Johnston MI; Fauci AS N Engl J Med; 2011 Sep; 365(10):873-5. PubMed ID: 21899447 [No Abstract] [Full Text] [Related]
6. Antibodies: beyond neutralization. von Bubnoff A IAVI Rep; 2010; 14(1):8-12. PubMed ID: 20349583 [No Abstract] [Full Text] [Related]
7. Emerging concepts on the role of innate immunity in the prevention and control of HIV infection. Ackerman ME; Dugast AS; Alter G Annu Rev Med; 2012; 63():113-30. PubMed ID: 22077718 [TBL] [Abstract][Full Text] [Related]
8. New center focuses on neutralizing antibodies. McEnery R IAVI Rep; 2008; 12(5):15. PubMed ID: 20210066 [No Abstract] [Full Text] [Related]
9. The 2017 Keystone Symposium on HIV Vaccines. Cottrell CA; Ward AB Hum Vaccin Immunother; 2017 Oct; 13(10):2348-2351. PubMed ID: 28786733 [No Abstract] [Full Text] [Related]
10. Infectious disease. An enterprising time for HIV vaccine research. Cohen J Science; 2012 Sep; 337(6101):1446. PubMed ID: 22997300 [No Abstract] [Full Text] [Related]
11. [The new vaccine challenges of "humanization" of HIV]. Nau JY Rev Med Suisse; 2013 Aug; 9(394):1490-1. PubMed ID: 24024395 [No Abstract] [Full Text] [Related]
12. The RV144 Thai HIV vaccine trial. Plotkin SA Hum Vaccin; 2010 Feb; 6(2):159. PubMed ID: 20431337 [No Abstract] [Full Text] [Related]
14. Opening Fronts in HIV Vaccine Development: Tracking the development of broadly neutralizing antibodies. Gruell H; Klein F Nat Med; 2014 May; 20(5):478-9. PubMed ID: 24804756 [No Abstract] [Full Text] [Related]
15. Ending AIDS--is an HIV vaccine necessary? Fauci AS; Marston HD N Engl J Med; 2014 Feb; 370(6):495-8. PubMed ID: 24499210 [No Abstract] [Full Text] [Related]
16. A brief history of the global effort to develop a preventive HIV vaccine. Esparza J Vaccine; 2013 Aug; 31(35):3502-18. PubMed ID: 23707164 [TBL] [Abstract][Full Text] [Related]
17. AIDS research. Novel antibody response may explain HIV vaccine success. Cohen J Science; 2011 Sep; 333(6049):1560. PubMed ID: 21921167 [No Abstract] [Full Text] [Related]
18. HIV vaccine development: challenges and opportunities towards solving the HIV vaccine-neutralizing antibody problem. Koff WC Vaccine; 2012 Jun; 30(29):4310-5. PubMed ID: 22100891 [TBL] [Abstract][Full Text] [Related]
19. Current world literature. Curr Opin HIV AIDS; 2009 Sep; 4(5):453-7. PubMed ID: 20046137 [No Abstract] [Full Text] [Related]
20. Making it to manufacturing. The potential success of broadly neutralizing monoclonal antibodies for HIV prevention, treatment, and possibly even a cure could come at a cost. Dumiak M IAVI Rep; 2014; 18(2):4-7, 17. PubMed ID: 25105201 [No Abstract] [Full Text] [Related] [Next] [New Search]